Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3029% above fair value
$515.02−5.64 (-1.08%)
Close on Nov 20, 2026Market cap $130.54BP/E 30.0Yield –
Vertex Pharmaceuticals Marketable securities by Quarter
Marketable securities ($M) ($M)
Vertex Pharmaceuticals Marketable securities: $1,709M in Q2 2026, up 21.1% from a year earlier.
Latest, Q2 2026
1,709
Period ended Jun 30, 2026
Change on a year earlier
+21.1%
1,411 in Q2 2025
History
35 quarters
Since Q4 2017
Sources
32
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K (DB).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Vertex Pharmaceuticals Marketable securities ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/fs-st-inv
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?